Their areas of expertise span the natural sciences, humanities, fine arts and social sciences, and the funds from the Connor Fellowship are intended to help each rising academic further their research ...

Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, ...

Shares of Scholar Rock Holding ( SRRK 13.36%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 ...

Scholar Rock (NASDAQ: SRRK) has reported positive results from the phase 2 Embraze trial, demonstrating statistically ...

The 30-stock Dow lost 44.14 points, or 0.10%, and ended at 42,171.66. The S&P 500 slipped 0.03% to close at 5,980.87, and the ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...

Investing.com -- Scholar Rock Holding Corp (NASDAQ: SRRK) stock surged 16.4% after the company announced positive results from its Phase 2 EMBRAZE trial evaluating apitegromab in combination with ...

Wall Street's main indexes ticked up on Wednesday, as investors awaited the Federal Reserve's monetary policy decision, while the Israel-Iran attacks entered the sixth day.

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.